Clinical pharmacokinetics of nebivolol: a systematic review

奈比洛尔 医学 药理学 药代动力学 最大值 不利影响 兰索拉唑 内科学 奥美拉唑 血压
作者
N. Hanif,Ammara Zamir,Imran Imran,Hamid Saeed,Abdul Majeed,Anees Ur Rehman,Waseem Ashraf,Faleh Alqahtani,Muhammad Fawad Rasool
出处
期刊:Drug Metabolism Reviews [Informa]
卷期号:55 (4): 428-440 被引量:1
标识
DOI:10.1080/03602532.2023.2271195
摘要

AbstractNebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile dysfunction, vascular disease, and diabetes mellitus. This review investigated the data regarding pharmacokinetic (PK) parameters, drug-drug interactions, dextrorotatory (D), and levorotatory (L) stereoisomers of nebivolol. The articles related to the PK of nebivolol were retrieved by searching the five databases; Google Scholar, PubMed, Cochrane Library, ScienceDirect, and EBSCO. A total of 20 studies comprising plasma concentration-time profile data following the nebivolol’s oral and intravenous (IV) administration were included. The area under the concentration-time curve from zero to infinity (AUC0-∞) was 15 times greater in poor metabolizers (PMs) than in extensive metabolizers (EMs). In hypertensive patients, L–nebivolol expressed a higher maximum plasma concentration (Cmax) than D–nebivolol, i.e. 2.5 ng/ml vs 1.2 ng/ml. The AUC0-∞ of nebivolol was 3-fold greater in chronic kidney disease (CKD). The clearance (CL) was increased in obese than in controls from 51.6 ± 11.6 L/h to 71.6 ± 17.4 L/h when 0.5 mg/ml IV solution was infused. Nebivolol showed higher Cmax, AUC0-∞ and half-life (t1/2) when co-administered with bupropion, duloxetine, fluvoxamine, paroxetine, lansoprazole, and fluoxetine. This concise review of nebivolol would be advantageous in assessing all PK parameters, which may be crucial for clinicians to avoid drug-drug interactions, prevent adverse drug events and optimize the dosage regimen in diseased patients diagnosed with hypertension and cardiovascular disorders.Keywords: Nebivololbeta-blockersPK parameterssystematic reviewD and L enantiomersCYP2D6 genotypehypertension Availability of dataAll the data supporting the results used for this publication is presented in the main article or in the Supplementary Information.Disclosure statementThe authors declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.Additional informationFundingThis work was funded by the Distinguished Scientist Fellowship program at King Saud University, Riyadh, Saudi Arabia, through research supporting project number (RSP2023R131).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李健应助lyrtim采纳,获得10
刚刚
深情安青应助嘎嘎采纳,获得10
4秒前
蓝微言应助sy采纳,获得10
4秒前
kevimfr发布了新的文献求助10
5秒前
陈咬金完成签到 ,获得积分10
5秒前
蜉蝣发布了新的文献求助10
8秒前
9秒前
0376驳回了情怀应助
9秒前
10秒前
琴l发布了新的文献求助20
10秒前
孤岛飞鹰完成签到,获得积分10
13秒前
戒灵发布了新的文献求助10
14秒前
丘比特应助13采纳,获得10
14秒前
搜集达人应助沉默白猫采纳,获得10
14秒前
义气的嘉熙完成签到,获得积分10
14秒前
14秒前
Gyumomo发布了新的文献求助10
16秒前
18秒前
19秒前
20秒前
戒灵完成签到,获得积分10
22秒前
chenc完成签到,获得积分10
23秒前
xch发布了新的文献求助10
24秒前
24秒前
Jasper应助清秀的怀蕊采纳,获得10
24秒前
可可发布了新的文献求助10
24秒前
夏远航完成签到,获得积分10
26秒前
27秒前
Hao应助自然傲柔采纳,获得10
28秒前
30秒前
蜉蝣发布了新的文献求助10
31秒前
深情安青应助韦老虎采纳,获得10
31秒前
nian完成签到,获得积分20
33秒前
33秒前
34秒前
34秒前
35秒前
35秒前
Supermao发布了新的文献求助10
36秒前
36秒前
高分求助中
请在求助之前详细阅读求助说明!!!! 20000
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
The Three Stars Each: The Astrolabes and Related Texts 900
Yuwu Song, Biographical Dictionary of the People's Republic of China 800
Multifunctional Agriculture, A New Paradigm for European Agriculture and Rural Development 600
Bernd Ziesemer - Maos deutscher Topagent: Wie China die Bundesrepublik eroberte 500
A radiographic standard of reference for the growing knee 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2477313
求助须知:如何正确求助?哪些是违规求助? 2141114
关于积分的说明 5457724
捐赠科研通 1864354
什么是DOI,文献DOI怎么找? 926822
版权声明 562872
科研通“疑难数据库(出版商)”最低求助积分说明 495905